VIDEO: ALK2 inhibitor can control hepcidin levels in myelofibrosis
Click Here to Manage Email Alerts
In this video, Idoroenyi Amanam, MD, discussed a study presented at ASCO Annual Meeting, that looked an ALK2 inhibitor along with ruxolitinib in the treatment of anemia in myelofibrosis.
Amanam, an assistant professor in the Division of Leukemia at City of Hope Cancer Center, highlighted the study, which showed anemia improvement with strong control of hepcidin when mixing ALK2 inhibitor along with ruxolitinib (Jakafi, Incyte).
“In that setting I think it will be really important to look at those patients who are JAK inhibitor naive,” Amanam said. “Will they be able to have better responses up front? But it seems like a manageable safety profile, and there’s the signal of efficacy.”
Collapse
Read more about
Click Here to Manage Email Alerts